That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...
Asthma causes inflammation and narrowing of the airways, making it harder to breathe. Symptoms may include wheezing, coughing, chest tightness, and shortness of breath. These symptoms can vary in ...
7 asthma medications: A guide to learn more Asthma is a chronic respiratory condition that affects millions of people of all ages. While there is no cure, modern asthma medications make it possible ...
GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...
GSK plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and ...
Investor's Business Daily on MSN
GSK digs in on allergies with $2.2 billion Rapt Therapeutics buyout
GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.
The Daily Overview on MSNOpinion
GSK grabs RAPT for $2.2B in big bet on food allergy drugs
GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...
Omalizumab or dupilumab suggested for adults with moderate-to-severe allergic asthma, history of exacerbations requiring oral corticosteroids ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results